Leukemic cells with SAMHD1 expression ablated using CRISPR/Cas9 are hypersensitive to nelarabine [46] and subsequently a thorough analysis of SAMHD1 expression and ara-G/nelarabine sensitivity in ALL revealed that the lack of SAMHD1 expression in T-ALL could largely account for the differential sensitivity as compared to B-ALL [47]. The gene discussed is SAMHD1; the disease is acute lymphoblastic leukemia.